Neogap Therapeutics

Neogap Therapeutics is a privately held, clinical-stage biotech company based in Stockholm, Sweden, pioneering personalized T cell therapies for solid tumors. The company's core innovation is a two-part platform combining the PIOR® software for neoantigen prediction with the EpiTCer® method for T cell training and expansion. With a recent SEK 87 million financing round, Neogap is advancing its lead pTTL therapy through clinical development, initially targeting colorectal cancer patients with limited treatment options. The company operates from the Karolinska Institute campus, leveraging a strong academic and industry team.

Proprietary two-part platform: PIOR® software for machine learning-based neoantigen prediction and selection, and EpiTCer® method for ex vivo training and expansion of patient T cells against selected neoantigens.

Neogap competes in the emerging field of personalized neoantigen-targeting therapies, facing competition from other biotechs developing similar T cell therapies, cancer vaccines, and mRNA-based approaches. It also competes for funding and partnership attention in a crowded immuno-oncology space dominated by checkpoint inhibitors and targeted therapies.